BACE1 and Parkinson disease: As concerns bioassays on isolated targets, different miniaturized alternatives have been established for High-Throughput Screening (HTS) of small molecules active in distinct pathways in AD/PD, i.e., UV–Vis, chemiluminescence- or fluorescence-based approaches to screen for binding partners of Aβ isoforms [e.g., ThioflavinT assay (Lee S. et al., 2023)] and tau oligomers, as well as of BACE1 (beta-secretase 1), TDP-43 (Buratti et al., 2013), ApoE (Chen et al., 2012), which among others include Fluorescence Resonance Energy Transfer (FRET) assays [e.g., AlphaScreen (Ren et al., 2013)].